The introduction of immunotherapy, starting with ipilimumab in 2011, revolutionized advanced melanoma treatment. Before this, a diagnosis was often a death sentence. The impact is quantifiable, with annual deaths dropping from nearly 14,000 to around 8,000, showcasing a dramatic shift in prognosis.

In the Keynote 522 trial for early-stage TNBC, adding pembrolizumab to chemotherapy resulted in only a modest improvement in pathological complete response (pCR). Surprisingly, this small initial gain translated into much more robust and significant long-term improvements in event-free and overall survival.

Positive Phase 3 trials in intermediate HCC met their primary Progression-Free Survival (PFS) endpoints. Criticizing them for not showing an overall survival benefit—an endpoint they weren't powered for—is a retrospective invalidation that risks discarding clinically meaningful advances.

When communicating with anxious, newly diagnosed patients, oncologists can point to the long-term survival 'tail' on modern immunotherapy trial curves. Simply stating, 'there is a chance that you will be alive and well,' provides crucial hope, reduces anxiety, and helps patients better engage with their treatment plan.

Similar to findings in small cell lung cancer, immunotherapy combinations in advanced ovarian cancer may create a "tail on the curve." Even if median survival benefit is modest, data shows the survival curves remain separated long-term, suggesting a small but significant subset of patients achieves durable survival of 3-5 years.

Immunotherapy is now inducing complete responses in a small subset of advanced HCC patients. This success presents a novel challenge, as there is no data to guide decisions on treatment duration, forcing difficult discussions about stopping therapy in patients who may be cured.

Dr. Carbone argues that traditional metrics like median survival or response rate are less relevant for immunotherapies. The true measure of success is the percentage of patients alive at five or six years—the "tail of the curve"—as this indicates a durable, potentially curative, response.

An overall survival (OS) benefit in an adjuvant trial may not be meaningful for patients in systems (e.g., the U.S.) with guaranteed access to the same effective immunotherapy upon recurrence. The crucial, unanswered question is whether treating micrometastatic disease is inherently superior to treating macroscopic disease later, a distinction current trial data doesn't clarify.

Immunotherapies can be effective even without causing significant tumor shrinkage. Immunocore's drug KimTrack had a low 5-7% objective response rate (ORR) but demonstrated a massive overall survival (OS) benefit, challenging the reliance on traditional chemotherapy metrics for evaluating modern cancer treatments.